Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C2 | P52895 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286756 | 0.84 | KDM4E (0.49) | MEN1MAPTKMT2ATDP1GAA | |
| SCHEMBL6287887 | 0.84 | HDAC1 (0.59) | AKR1C2HDAC1MEN1MAPTKMT2A | |
| SCHEMBL7034718 | 0.83 | HDAC1 (0.63) | AKR1C2HDAC1MEN1MAPTKMT2A | |
| SCHEMBL6290890 | 0.82 | HDAC1 (0.68) | AKR1C2HDAC1 | |
| SCHEMBL6287588 | 0.81 | HDAC1 (0.63) | AKR1C2HDAC1MEN1MAPTKMT2A | |
| SCHEMBL6287519 | 0.81 | HDAC1 (0.65) | AKR1C2HDAC1 | |
| SCHEMBL6284082 | 0.81 | HDAC1 (0.60) | AKR1C2HDAC1MEN1MAPTKMT2A | |
| SCHEMBL7960856 | 0.81 | AKR1C2 (0.67) | AKR1C2HDAC1MEN1MAPTKMT2A | |
| SCHEMBL6287501 | 0.80 | HDAC1 (0.69) | AKR1C2HDAC1 | |
| SCHEMBL4245651 | 0.80 | MAPT (0.65) | AKR1C2HDAC1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887890-B2 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-08-28 | — | — | US | disclosed |
| EP-1291341-A1 | COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162724-A1 | Compounds exhibiting thrombopoietin-like activities | MPL, THPO, TEK | AKR1C2 2816/4885HDAC1 3488/4885MEN1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.